WVS | ANYX: Latest Product is Based on Atomization Technology G-mesh

World Vape Show by 2FIRSTS
Jun.14.2024
WVS | ANYX: Latest Product is Based on Atomization Technology G-mesh
World Vape Show in Dubai featured ANYX brand leader Sanking discussing market performance, new products, and future plans.

The World Vape Show was held at the Dubai World Trade Center from June 12th to 14th. During the event, 2FIRSTS had a conversation with Sanking, the head of Anyx, a brand under the Yijiate Group, where he discussed the market performance of Anyx, new products, and future development plans.

WVS | ANYX: Latest Product is Based on Atomization Technology G-mesh
ANYX booth | Image source: 2FIRSTS

 

According to Sanking, the ANYX brand specializes in pod systems, including both open and closed systems, and also has entered the disposable e-cigarette market. The brand is continuously innovating its technology and has recently launched four new products, including Anyx-pro, Anyx-go, Anyx-polo, and Anyx-max.

WVS | ANYX: Latest Product is Based on Atomization Technology G-mesh
ANYX booth | Image source: 2FIRSTS

 

Sanking stated that ANYX primarily focuses its market in Europe, particularly in Italy and Spain, as well as in South America, the Middle East, and Southeast Asia, with the best performance seen in the Italian market. The brand name "ANYX" combines "any + possible," symbolizing endless possibilities and emphasizing user needs and perception.

 

This is ANYX's first participation in the world e-cigarette exhibition in Dubai. The Middle East market is a completely new territory for ANYX, as the brand only started expanding into this market at the end of 2022. Sanking stated that despite being a relatively new brand, the Middle East market will be a strategic focus for future extensive deployment.

 

At this exhibition, ANYX showcased its latest atomization core technology G-mesh and the products using it. While ANYX introduced a large-screen e-cigarette based on cartridge replacement, it remains cautious towards disposable large-screen e-cigarettes due to concerns about resource waste and environmental issues.

 

Sanking stated that the Middle East market has tremendous potential, and ANYX is currently in discussions with multiple local distributors for collaboration. The brand's plan is to combine online and offline experiences and user operations to increase market share. In the future, ANYX will launch products that better cater to the preferences of local consumers based on market demand, and will collaborate deeply with local partners.

 

Sanking stated that ANYX will focus on the European market and continue to explore opportunities in other emerging markets in the future. The brand will introduce products tailored to consumer demands based on market conditions, aiming to enhance user experience through technological innovation.

 

Finally, Sanking gave high praise to the e-cigarette exhibition in Dubai, considering it the largest in the world with significant influence. The large number of exhibitors, distributors, and visitors, along with intense competition, reflects the industry's enormous potential and development trends.

 

He called on all industry participants to focus on the product itself and user experience, rather than solely concentrate on price wars.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11
HB 5437 “Vape Safety Act” advances in House committee, proposing statewide licensing for vape shops
HB 5437 “Vape Safety Act” advances in House committee, proposing statewide licensing for vape shops
A committee substitute for House Bill 5437, the Vape Safety Act sponsored by Del. David McCormick (David McCormick), was recommended Monday afternoon by the House Health and Human Resources Committee to the full House, with the bill next heading to the House Judiciary Committee. HB 5437 would require specialty shops selling tobacco, tobacco-derived products, alternative nicotine, or vapor products and accessories to obtain a state license from the Alcohol Beverage Control Administration (ABCA)
Feb.26 by 2FIRSTS.ai
Austintown PTA hosts “Live Vape Free” town hall to discuss teen vaping risks and prevention
Austintown PTA hosts “Live Vape Free” town hall to discuss teen vaping risks and prevention
The Austintown Parent Teacher Association hosted a “Live Vape Free” town hall to discuss the dangers of vaping devices among middle and high schoolers, the report said. The event was funded by the National PTA Vape-Free Futures Challenge Grant, provided in collaboration with the Campaign for Tobacco-Free Kids, and Austintown was one of seven PTAs nationwide to receive it.
Feb.27 by 2FIRSTS.ai
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
Turning Point Brands, a U.S. nicotine and tobacco-related consumer products company, reported its fiscal 2025 fourth-quarter results: quarterly revenue was $121 million, up 29% year over year; adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) was $30 million, up 14%. Net revenue from modern oral nicotine products was $41.3 million, up 266% year over year.
Mar.03 by 2FIRSTS.ai
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Breeze Smoke and Glas, Inc. have separately requested White House review under Executive Order 12866 as the FDA advances draft guidance on flavored ENDS (RIN 0910-ZC78). The guidance aims to clarify evidentiary standards under the statutory “appropriate for the protection of public health” (APPH) framework. The parallel filings highlight industry concern over regulatory predictability, particularly as Glas’s PMTA review status has recently drawn market attention.
Special Report
Mar.03
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11